Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open Ophth

Supplemental Table 2: Change in prevalence of optical coherence tomography (OCT) features in patients with Best vitelliform macular dystrophy over time.

	Baseline	Follow-up	*p*-value
Number of Eyes	65		-
Follow-up Period [Years] (mean, median, range)	5.1, 5, 1 to 11		-
Age [Years] (mean, median, range)	40.1, 42.0, 4 to 84	45.1, 50.0, 8 to 89	0.12
LogMAR BCVA (mean, median, range)	0.34, 0.3, -0.12 to 1.0	0.27, 0.20, -0.52 to 0.90	0.18
% Eyes with BCVA ≥ 20/50	60	65	0.33
CST [µm] (mean, median, range)	359.7, 329, 177 to 627	340, 321, 142 to 629	0.17
Feature Rate (%)			
Pre-VL	10.8	3.1	0.23
Solid VL	10.8	15.4	0.33
SRF	7.7	7.4	0.38
Pillar	21.5	21.5	0.50
FCE	13.9	26.2	0.11
IRF	16.9	16.9	0.50
Atrophy	9.2	15.4	0.55
CNV	15.4	18.5	0.38

Abbreviations: BCVA: best corrected visual acuity; Pre-VL: pre-vitelliform; VL: vitelliform; SRF: subretinal fluid; FCE: focal choroidal excavation; IRF: intraretinal fluid; VA: visual acuity; CST: central subfield thickness; CNV: choroidal neovascularization. P-value <0.05 considered statistically significant.